ArticleInternational journal of cancer2018
Type 2 diabetes and colorectal cancer survival: The multiethnic cohort.
Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07084350 (Efficacy and Safety of Oral Lactulose Combined With Polyethylene Glycol Electrolytes Powder), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Oral Lactulose Combined With Polyethylene Glycol Electrolytes Powder (PEG-ELS) for Bowel Preparation in Type II Diabetes Mellitus Patients: A Randomized Controlled Trial
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Temporal Trends in Colorectal Cancer Associated With Type 2 Diabetes Mellitus in U.S. Adults, 1999-2023: A CDC Wonder Database Analysis-A Population-Based Cross-Sectional Study.Health science reports · 2026Article
- The rising burden of obesity-linked cancers in Saudi Arabia: a public health review.Annals of medicine and surgery (2012) · 2026Article
- Type II diabetes and metformin use does not affect colorectal cancer prognosis.International journal of cancer · 2025Article
- Associations of diabetes and mortality among colorectal cancer patients from the Southern Community Cohort Study.British journal of cancer · 2024Article
- Investigating the Obesity Paradox in Colorectal Cancer: An Analysis of Prospectively Collected Data in a Diverse Cohort.Cancers · 2024Article
- Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024Review
- High glucose inhibits autophagy and promotes the proliferation and metastasis of colorectal cancer through the PI3K/AKT/mTOR pathway.Cancer medicine · 2024Article
- Type 2 Diabetes Mellitus and Non-Metastatic Colorectal Cancer: A Retrospective Study on Survival and Toxicity Profiles.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Influence of the duration of type 2 diabetes mellitus on colorectal cancer outcomes.Scientific reports · 2023Observational
- Marked paper: Type 2 diabetes mellitus indicates increased postoperative complications and poor prognosis in colorectal cancer patients receiving curative surgery.Frontiers in oncology · 2023Article
- The prognostic role of fasting plasma glucose levels on survival in advanced colorectal cancer patients with type II diabetes mellitus: a retrospective cohort study.Journal of gastrointestinal oncology · 2022Article
- Impact of Diabetes on Short-Term and Long-Term Outcomes of Ampullary Adenocarcinoma Patients after Curative Pancreatoduodenectomy.Current oncology (Toronto, Ont.) · 2022Article
- The joint association of cardiometabolic health and weight on mortality in the multiethnic cohort.Ethnicity & health · 2022Article
- The Effect of Type 2 Diabetes Mellitus on the Short-Term Outcomes and Prognosis of Stage I-III Colorectal Cancer: A Propensity Score Matching Analysis.Cancer management and research · 2022Article
- Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions.Molecular oncology · 2022Article
- Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Diabetes and cancer: Epidemiological and biological links.World journal of diabetes · 2020Review
- Pre- and Post-diagnosis Diabetes as a Risk Factor for All-Cause and Cancer-Specific Mortality in Breast, Prostate, and Colorectal Cancer Survivors: a Prospective Cohort Study.Frontiers in endocrinology · 2020Article
- Progressive Shifts in the Gut Microbiome Reflect Prediabetes and Diabetes Development in a Treatment-Naive Mexican Cohort.Frontiers in endocrinology · 2020Article
- Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
This analysis examined type 2 diabetes (T2D) as a predictor of colorectal cancer (CRC) survival within the Multiethnic Cohort Study. Registry linkages in Hawaii and California identified 5,284 incident CRC cases. After exclusion of cases with pre-existing cancer diagnosis within 1 year and systemic disease, the analytic dataset had 3,913 cases with 1,800 all-cause and 678 CRC-specific deaths after a mean follow-up of 9.3 ± 5.2 years. Among CRC cases, 707 were diagnosed with T2D 8.9 ± 5.3 years before CRC. Cox regression with age as time metric was applied to estimate hazard ratios (HR) and 95% confidence intervals (CI) for T2D status as predictor of CRC-specific and all-cause survival while adjusting for known confounders. Overall, CRC-specific survival was not associated with pre-existing T2D (HR = 0.84; 95% CI = 0.67-1.07). However, a significant interaction was seen for comorbidity (p
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.